What the Shift the Value Means for Pharmaceuticals


About this Webinar

With the transition to value, payers are insisting that pharmaceutical manufacturers deliver real world evidence of their drug’s efficacy before being allowed on formulary. The cost of new specialty treatments has forced companies to bolster and go beyond clinical trial, proving that their drugs improve health outcomes and reduce the cost of care with real world evidence.


So how do pharmaceutical companies gather these data points and what kind of tools should they use? Join our hosts for this discussion of the shift to value. 

Watch it now

Complete this form to view the webinar.

About the Speakers

Todd Greenwood, PhD, MPH - Director of Digital Strategy

With decades of experience in the healthcare sector, Todd has partnered with clients across the industry to plan and deliver actionable, buildable solutions that show real world results. He has especially focused on patient engagement and education, healthcare brand marketing, and market access strategies.


Benjamin Dean - Business and Monetization Strategist

Leveraging his background in venture capital, finance, and asset securitization, Ben is a leader in developing business models and monetization strategies for innovative digital health products. Recently, he has focused on digital health market access, real world evidence, and healthcare delivery business development.

Linkedin Twitter

Join Our Mailing List

Fresh content delivered right to your inbox from us at Medullan.